Relmada Therapeutics Inc ($RLMD) announced an update on their ongoing clinical study. Relmada Therapeutics is preparing to launch a late-stage ...

While the current approval focuses on the second-line setting, research is already moving into earlier stages of the ...

There is a significant unmet need for additional treatment options for high-grade NMIBC, especially in those ineligible for BCG.

Two applicants will each receive a Grant of $50,000 to support the development of outstanding clinical cancer research to improve the treatment ...

Kolschowsky Research and Education Institute at Sarasota Memorial Hospital is seeking candidates diagnosed with ...

Protara Therapeutics announced promising results from its Phase 2 ADVANCED-2 trial for TARA-002, an investigational therapy for high-risk non-muscle invasive bladder cancer (NMIBC). The study shows a ...

RARITAN, N.J., July 17, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) granted Priority Review to the New Drug Application (NDA) ...

LAS VEGAS -- Patients with high-risk, treatment-unresponsive non-muscle invasive bladder cancer (NMIBC) had an unprecedented response rate and disease-free survival (DFS) with an investigational ...

Nearly 20,000 women are diagnosed with bladder cancer each year, according to the American Cancer Society, with most being ...

When you learn you have bladder cancer, it’s only natural to ask: "Can I survive this, for how long, and can I expect to be cured?" You may have searched online for survival rate information. These ...